#2 - Crispr Therapeutics (NASDAQ:CRSP)
Gene editing was one of the most promising technologies that fell to the back burner a little due to the pandemic. In layman’s terms Crispr Therapeutics (NASDAQ:CRSP) looks for anomalies in an individual’s genetic sequence. When an anomaly is identified, the company uses a protein called Cas9 to cut out the anomaly and replace it.
It’s not simple, and that’s the reason the company has not yet delivered a product to market. However, that may be changing. The company is currently working to mass-produce cell therapies that will work in any individual. And its in-house therapy for non-Hodgkin’s lymphoma (CTX110) is already through Phase 1 trials.
Investors who are unfamiliar with Crispr Technologies may look at the company’s stock chart and get a bit spooked. You shouldn’t. CRSP stock is down nearly 20% from its mid-January high. But this is likely due to profit-taking.
The stock pushed through an important level of resistance at $70 in early summer and was marching steadily forward. The price of CRSP stock accelerated at the start of the year, but the recent selloff creates a good buying opportunity.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Read More - Current Price
- $55.89
- Consensus Rating
- Hold
- Ratings Breakdown
- 8 Buy Ratings, 6 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $76.29 (36.5% Upside)
